The investment bank upgraded the steel producer to overweight from equal weight.
Category: Uncategorized
CFTC’s Innovation Advisory Committee meeting addresses emerging prediction market risks
The CFTC’s first Innovation Advisory Committee meeting discussed risks of mention markets, with members advocating for tighter consumer protection.
Friday’s big stock stories: What’s likely to move the market in the next trading session
The Dow Industrials dropped 700 points on Thursday as Treasury yields resumed their climb and the Treasury Department’s relief plan failed.
Wall Street loves these high-yielding AI bonds. What income investors should know
Investors can grab sweet yields from hyperscaler bonds. Issuance has surged as the companies look to fund their artificial intelligence buildout.
Yields are on the move once again. These stocks could get a boost if they keep going higher
Using LSEG data, CNBC Pro screened the S&P 1500 for stocks with the strongest negative 60-day correlations to the iShares 20+ Year Treasury Bond ETF (TLT).
Meta shares seem cheap, but the charts are showing an ominous sign, says Jay Woods
The social media giant looks like a screaming buy based on certain metrics, but the charts show a foreboding pattern.
A household appliance maker made it into Josh Brown’s Best Stocks list this month. It is soaring in 2026
This stock has been on a tear since being spun off in 2023.
This Kansas City regional bank is playing with the big boys. JPMorgan sees big gains ahead
UMB Financial is expanding its services, making it more like a big bank and offering it more avenues to grow, according to JPMorgan.
This fertility benefit business is set to boom. Buy the stock now, Wells Fargo says
Progyny is set to benefit from several structural tailwinds, including catalysts that should help it court more clients, according to Wells Fargo.
Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley says
Merck, which makes the popular cancer treatment Keytruda, is poised to gain ground as its pipeline drugs get close to coming to market, per Morgan Stanley.